Bluejay Diagnostics (BJDX) as of March 31, 2026 presents a deeply negative liquidation recovery posture for equity holders. The company is a pre-revenue medical diagnostics developer with zero operating income since inception and an accumulated deficit of $43.4 million. Under a liquidation lens, recoverable assets are dominated by cash ($3.68 million at 100% recovery) plus modest prepaid expenses ($270K, applying ~50-60% haircut yields ~$135-160K), and net PP&E of $1.53 million. The PP&E composition is critical: $1.29 million sits in construction-in-process (CIP) consisting of Symphony cartridge manufacturing equipment held and operated by Sanyoseiko in Japan, and $200K of manufacturing equipment at the same CMO. Liquidation recovery on foreign-held, specialized pre-commercial manufacturing equipment is at best 20-30 cents on the dollar given illiquidity, single-buyer risk, and geographic concentration. Applying a 25% haircut to CIP and manufacturing equipment at Sanyoseiko, a 50-60% haircut to remaining FF&E and leasehold improvements, aggregate PP&E liquidation recovery is approximately $350-450K against $1.53 million book. Operating ROU asset ($91K) has zero residual value under liquidation. Total estimated asset recovery: approximately $4.2-4.4 million. Against this, total liabilities at face value are only $1.42 million, nearly all current, including $1.10 million in accrued expenses and other current liabilities. Lease obligations total $105K (operating plus finance). There are no long-term debt instruments. On a purely mechanical basis, estimated net liquidation recovery to equity is modestly positive at approximately $2.8-3.0 million, broadly consistent with the MFFAIS CLV/LLV/OLV of $2.27 million which applies more conservative haircuts to PP&E. The going-concern risk, however, is acute: management explicitly states cash resources will be sufficient only through Q3 2026, the company needs to raise at least $20 million by end of 2027 to execute its plan, and the board has acknowledged it could initiate Chapter 7 proceedings if financing fails. The March 2026 private placement raised only $125K from insiders at $2.00/share — a de minimis financing that signals constrained external demand. Accrued clinical trial expenses jumped from $275K to $490K quarter-over-quarter, consistent with ongoing SYMON-II enrollment costs that will continue to consume cash. The operating cash burn of $1.59 million in Q1 2026 (versus $1.18 million in Q1 2025, a 34% increase) means the stated runway is approximately 2.3 quarters at current burn. No intangible assets are separately tagged in XBRL; the filing discusses IP licensed from Toray Industries and Bluejay's own IP in MD&A but does not separately tag or carry intangible asset value on the balance sheet. Under the liquidation lens, those IP rights receive zero recovery given their pre-clearance, pre-commercial status. The prior filing (10-K for FY2025, period end December 31, 2025) showed total stockholders' equity of $5.98 million; Q1 2026 net loss of $1.92 million reduced this to $4.18 million. The liability stack is unchanged in structure but accrued expenses increased $292K, primarily from clinical trial cost accruals and personnel bonuses.
▼ Community Notes